Floatz logo

Therapeutic Asset Ratings

615 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
TRASTUZUMAB
Hormone Receptor Positive Tumor
Fudan UniversityP2CCC (53)
TRASTUZUMAB
Intestinal Neoplasm
Fudan UniversityP2CCC (53)
Tuvonralimab
Ovarian Cancer
Fudan UniversityP2CCC (53)
Tuvoraleimab
Acral Lentiginous Melanoma
Fudan UniversityP2CCC (53)
Tuvoraleimab
Mucosal Melanoma
Fudan UniversityP2CCC (53)
utd1
Breast Neoplasm
Fudan UniversityP2CCC (53)
utd1
Hormone Receptor Positive Tumor
Fudan UniversityP2CCC (53)
(+)-VINCRISTINE
Hormone Receptor Positive Tumor
Fudan UniversityP2CCC (53)
VINCRISTINE SULFATE
Maintenance Therapy
Fudan UniversityP2CCC (53)
Vinorelbine
Hormone Receptor Positive Tumor
Fudan UniversityP2CCC (53)
Zanubrutinib
Maintenance Therapy
Fudan UniversityP2CCC (53)
Zoladex
Hormone Receptor Negative Tumor
Fudan UniversityP2CCC (53)
dl-3-butylphthalide
Stroke Disorder
Fudan UniversityP3CCC (52)
FLAVONE, 3,3',4',5,7-PENTAHYDROXY-
Triple-Negative Breast Carcinoma
Fudan UniversityP2CCC (52)
Pyrotinib
Solid Tumor, Adult
Fudan UniversityP2CCC (52)
rc48-adc
Solid Tumor, Adult
Fudan UniversityP2CCC (52)
Tislelizumab
Solid Tumor, Adult
Fudan UniversityP2CCC (52)
Pralsetinib, trans-
RET Fusion Positive Cancer
Fudan UniversityP1/2CCC (52)
9mw2821
Breast Cancer
Fudan UniversityP2CCC (51)
Acetylsalicylic Acid
Metastatic Prostate Cancer
Fudan UniversityP2CCC (51)
Adebelimab
Metastatic Malignant Neoplasm
Fudan UniversityP2CCC (51)
ag-120
Metastatic Cancer
Fudan UniversityP2CCC (51)
Calcium folinate pentahydrate
Relapse
Fudan UniversityP2CCC (51)
Carboplatin
Intrahepatic Cholangiocarcinoma (Icc)
Fudan UniversityP2CCC (51)
Cetuximab
Relapse
Fudan UniversityP2CCC (51)
Showing 401 to 425 of 615 assets
PreviousPage 17 of 25Next